Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||LY2090314 + Simmiparib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|LY2090314||LY-2090314|LY 2090314||GSK3 Inhibitor (Pan) 3||LY2090314 inhibits glycogen synthase kinase 3 (GSK3), therefore activates Wnt signaling pathway and leads to apoptosis in tumor cells (PMID: 25915038, PMID: 26735141, PMID: 32391602).|
|Simmiparib||SMOCL-9112||PARP Inhibitor (Pan) 22||Simmiparib is an inhibitor of PARP1/2, which may induce DNA double-strand breaks, G2/M phase arrest, and apoptotic activity, and may lead to inhibition of tumor growth (PMID: 27847302).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colorectal cancer||not applicable||LY2090314 + Simmiparib||Preclinical - Cell culture||Actionable||In a preclinical study, the combination therapy of LY2090314 and Simmiparib resulted in a synergistic effect in colorectal cancer cells with either BRCA1/2 proficiency or BRCA2 deficiency in culture, demonstrating increased cell cycle arrest, apoptotic cell death, and decreased cell survival, and led to inhibition of tumor growth, increased double-strand DNA breaks, and elevated cleaved caspase 3 in cell line xenograft models (PMID: 33589588).||33589588|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|